Pronase to Improve Mucosal Clarity During Colonoscopy in Colitis
Tests pronase against saline in adults with colitis undergoing colonoscopy.
Plain-language title generated from the registry record
Registry title: Pronase in Improving Endoscopic Mucosal Clarity During Colonoscopy for Patients with Colitis
Key facts
- Where
- Shanghai, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06874673, who can take part
Where in China
- Changhai Hospital, Naval Medical UniversityShanghai, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Changhai Hospital
- Trial code
- NCT06874673
- Record updated
- 13 March 2025
- Original description
Pronase is a proteolytic enzyme known for its ability to clear mucus by breaking down its main component, mucin, through enzymatic hydrolysis. This property makes it useful in gastroscopy, where it is employed to improve the visibility of the mucosal surface during endoscopic examinations. Given the same mechanism, pronase may also be beneficial in enhancing mucosal clarity during colonoscopy. This multicenter, prospective, double-blind randomized controlled trial is designed to assess the effectiveness and safety of pronase in improving mucosal visibility in patients with colitis during endoscopy.Read full original descriptionShow less
A Multicenter, Prospective, Double-Blind Randomized Controlled Trial Evaluating the Efficacy and Safety of Pronase in Improving Endoscopic Mucosal Clarity During Colonoscopy for Patients with Colitis
Pronase is a proteolytic enzyme known for its ability to clear mucus by breaking down its main component, mucin, through enzymatic hydrolysis. This property makes it useful in gastroscopy, where it is employed to improve the visibility of the mucosal surface during endoscopic examinations. Given the same mechanism, pronase may also be beneficial in enhancing mucosal clarity during colonoscopy. This multicenter, prospective, double-blind randomized controlled trial is designed to assess the effectiveness and safety of pronase in improving mucosal visibility in patients with colitis during endoscopy.
Inclusion: Patients presenting with intestinal inflammation during colonoscopy, accompanied by mucus obscuring visualization, were included, particularly those with inflammatory bowel disease (IBD), regardless of the presence or absence of clinical symptoms such as abdominal pain, diarrhea, hematochezia, or mucoid stools; Researchers assessed the current health status of potential participants to ensure they could tolerate colonoscopy (based on physical examination and medical history); Age range was 18-75 years (inclusive); Participants provided written informed consent to participate voluntarily.
Exclusion: Participants who had taken antiplatelet medications (e.g., aspirin, clopidogrel) or had abnormal coagulation function within 7 days prior to colonoscopy; Participants with known hypersensitivity or allergy to the study medication; Participants with peritonitis, intestinal obstruction, severe intestinal infection, or radiation colitis; Participants with severe cardiovascular, pulmonary, neurological, or renal disease, or those deemed unfit for colonoscopy; Participants who did not exhibit intestinal mucus obscuring endoscopic visualization during colonoscopy; Participants who did not provide written informed consent or lacked the capacity to do so; Pregnant or breastfeeding women; Participants currently participating in other clinical observation trials or who had participated in another clinical trial within 60 days.